Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of timing of trastuzumab initiation on long-term outcome of patients with early-stage HER2-positive breast cancer: the "one thousand HER2 patients" project.
Gullo G, Walsh N, Fennelly D, Bose R, Walshe J, Tryfonopoulos D, O'Mahony K, Hammond L, Silva N, McDonnell D, Ballot J, Quinn C, McDermott EW, Evoy D, Prichard R, Geraghty J, Amstrong J, Crown J. Gullo G, et al. Among authors: tryfonopoulos d. Br J Cancer. 2018 Aug;119(3):374-380. doi: 10.1038/s41416-018-0114-x. Epub 2018 May 18. Br J Cancer. 2018. PMID: 29773838 Free PMC article.
Predictive biomarkers for dasatinib treatment in melanoma.
Eustace AJ, Kennedy S, Larkin AM, Mahgoub T, Tryfonopoulos D, O'Driscoll L, Clynes M, Crown J, O'Donovan N. Eustace AJ, et al. Among authors: tryfonopoulos d. Oncoscience. 2014 Mar 12;1(2):158-66. doi: 10.18632/oncoscience.20. eCollection 2014. Oncoscience. 2014. PMID: 25594008 Free PMC article.
Src: a potential target for the treatment of triple-negative breast cancer.
Tryfonopoulos D, Walsh S, Collins DM, Flanagan L, Quinn C, Corkery B, McDermott EW, Evoy D, Pierce A, O'Donovan N, Crown J, Duffy MJ. Tryfonopoulos D, et al. Ann Oncol. 2011 Oct;22(10):2234-40. doi: 10.1093/annonc/mdq757. Epub 2011 Feb 28. Ann Oncol. 2011. PMID: 21357651 Free article.
Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08-10 trial.
Gullo G, J Eustace A, Canonici A, M Collins D, Kennedy MJ, Grogan L, Breathhnach O, McCaffrey J, Keane M, Martin MJ, Gupta R, Leonard G, O'Connor M, Calvert PM, Donnellan P, Walshe J, McDermott E, Scott K, Hernando A, Parker I, W Murray D, C O'Farrell A, Maratha A, Dicker P, Rafferty M, Murphy V, O'Donovan N, M Gallagher W, Ky B, Tryfonopoulos D, Moulton B, T Byrne A, Crown J. Gullo G, et al. Among authors: tryfonopoulos d. Ther Adv Med Oncol. 2019 Jul 24;11:1758835919864236. doi: 10.1177/1758835919864236. eCollection 2019. Ther Adv Med Oncol. 2019. PMID: 31384312 Free PMC article.
Phase 2 study of cabazitaxel as second-line treatment in patients with HER2-negative metastatic breast cancer previously treated with taxanes-a Hellenic Cooperative Oncology Group (HeCOG) Trial.
Koutras A, Zagouri F, Koliou GA, Psoma E, Chryssogonidis I, Lazaridis G, Tryfonopoulos D, Kotsakis A, Res E, Kentepozidis NK, Razis E, Psyrri A, Koumakis G, Kalofonos HP, Dimopoulos MA, Fountzilas G. Koutras A, et al. Among authors: tryfonopoulos d. Br J Cancer. 2020 Aug;123(3):355-361. doi: 10.1038/s41416-020-0909-4. Epub 2020 Jun 3. Br J Cancer. 2020. PMID: 32488135 Free PMC article. Clinical Trial.
39 results